In Brief | Published:

ACUTE CORONARY SYNDROMES

Targeting PCSK9 to reduce residual risk in ACS

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1801174 (2018)

    Download references

    Author information

    Correspondence to Irene Fernández-Ruiz.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark